New platform trial takes on NF2 tumors with multiple drug strategies
NCT ID NCT07713745
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This trial tests several drugs in people with NF2-related schwannomatosis, a condition that causes tumors on nerves and in the brain. The study uses a flexible 'platform' design to evaluate treatments for four tumor types: vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas. Participants receive either selumetinib alone or a combination of luvometinib and serplulimab, with a separate observation group serving as a comparison.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selumetinib, luvometinib plus serplulimab
- What this could lead to
- If successful, this trial could identify effective drug treatments for multiple tumor types in NF2-related schwannomatosis, potentially shrinking tumors and improving hearing.
- What could go wrong
- This is an early-phase platform trial, so results are preliminary. Not all drugs may work, and side effects from the combinations could limit their use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPENDYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could blocking a Tumor's blood supply shrink brain meningiomas?
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
- Drug combo aims to shrink NF2 tumors and save hearing
- AI reads MRI scans to reveal hidden brain tumor types in children before surgery
- Targeted radiation zaps childhood brain tumors in early trial
- Radiation's hidden toll on the brain: new study maps cognitive changes to protect patients